The American journal of gastroenterology · 2025
A Prospective Interventional Study to Evaluate the Effect of Hypoxia on Healthy Volunteers and Patients With Inflammatory Bowel Disease: The Altitude Inflammatory Bowel Disease Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vavricka Stephan R, Zeitz Jonas, Madanchi Mehdi, Ruiz Pedro A, Biedermann Luc, Morsy Yasser, Yilmaz Bahtiyar, Scharl Michael, Scharl Sylvie, Gassmann Max, Lutz Thomas A, Kunz Andres, Bron Denis, Misselwitz Benjamin, MacPherson Andrew J, Rogler Gerhard, Greuter Thomas
Аннотация
INTRODUCTION: Retrospective data suggest association of high-altitude exposure and inflammatory bowel disease flares. Knowledge about underlying pathogenesis remains limited.
METHODS: This prospective interventional trial evaluated the effect of 3 hours hypobaric low-pressure chamber exposure on 11 patients with Crohn's disease (CD), 9 with ulcerative colitis (UC), and 10 controls.
RESULTS: Proportion of patients with clinical and endoscopic activity did not increase. However, 33.3% of patients with UC experienced a flare. More patients had calprotectin-based activity (>100 μg/g) after the intervention (26.7 vs 63.3%, P = 0.013). Transient changes in certain bacterial strains were seen in controls and patients with UC.
DISCUSSION: Low-pressure chamber exposure, although the primary outcome was not met, led to a flare in a third of patients with UC, with changes in calprotectin levels and specific bacterial strains ( Clinicaltrials.gov number, NCT02849821).
METHODS: This prospective interventional trial evaluated the effect of 3 hours hypobaric low-pressure chamber exposure on 11 patients with Crohn's disease (CD), 9 with ulcerative colitis (UC), and 10 controls.
RESULTS: Proportion of patients with clinical and endoscopic activity did not increase. However, 33.3% of patients with UC experienced a flare. More patients had calprotectin-based activity (>100 μg/g) after the intervention (26.7 vs 63.3%, P = 0.013). Transient changes in certain bacterial strains were seen in controls and patients with UC.
DISCUSSION: Low-pressure chamber exposure, although the primary outcome was not met, led to a flare in a third of patients with UC, with changes in calprotectin levels and specific bacterial strains ( Clinicaltrials.gov number, NCT02849821).